Untitled

doi:10.18632/oncotarget.v6i27

Cited by 10 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14,40 The central hypothesis was that this DRS probe would simultaneously sample the overlying epithelial skin layer as well as the subcutaneous tumor allograft by including multiple discrete SDSs and extract optical parameters from increasing depths. 14,41 DRS data at each SDS represent a weighted average of physiological parameters collected from increasing sampling depths. In the female Balb/c-CT26 colon tumor allograft model, the skin, consisting of the epidermis, dermis, and hypodermis was 0.71-AE 0.11-mm thick, and the underlying fascia resulted in 1.00 AE 0.15 mm of total tissue above the underlying subcutaneous tumor.…”

Section: Discussionmentioning

confidence: 99%

“…Specifically, DRS can be used in subcutaneous murine tumors that are used for a variety of research purposes including investigating the effects of potential therapies. 16 The central research question in this paper is: How can a DRS probe be optimally designed for evaluating tissue physiological parameters in subcutaneous murine tumors? At present, there have been no studies simultaneously quantifying wavelength-and SDS-dependent sampling depth in DRS probes with multiple channels to sample murine subcutaneous tumor allografts.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Sampling depth of a diffuse reflectance spectroscopy probe for in-vivo physiological quantification of murine subcutaneous tumor allografts

et al. 2018

View full text Add to dashboard Cite

Diffuse reflectance spectroscopy (DRS) is a probe-based spectral biopsy technique used in cancer studies to quantify tissue reduced scattering (μs') and absorption (μa) coefficients and vary in source-detector separation (SDS) to fine-tune sampling depth. In subcutaneous murine tumor allografts or xenografts, a key design requirement is ensuring that the source light interrogates past the skin layer into the tumor without significantly sacrificing signal-to-noise ratio (target of ≥15 dB). To resolve this requirement, a DRS probe was designed with four SDSs (0.75, 2.00, 3.00, and 4.00 mm) to interrogate increasing tissue volumes between 450 and 900 nm. The goal was to quantify percent errors in extracting μa and μs', and to quantify sampling depth into subcutaneous Balb/c-CT26 colon tumor allografts. Using an optical phantom-based experimental method, lookup-tables were constructed relating μa,μs', diffuse reflectance, and sampling depth. Percent errors were <10 % and 5% for extracting μa and μs', respectively, for all SDSs. Sampling depth reached up to 1.6 mm at the first Q-band of hemoglobin at 542 nm, the key spectral region for quantifying tissue oxyhemoglobin concentration. This work shows that the DRS probe can accurately extract optical properties and the resultant physiological parameters such as total hemoglobin concentration and tissue oxygen saturation, from sufficient depth within subcutaneous Balb/c-CT26 colon tumor allografts. Methods described here can be generalized for other murine tumor models. Future work will explore the feasibility of the DRS in quantifying volumetric tumor perfusion in response to anticancer therapies.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Sampling depth of a diffuse reflectance spectroscopy probe for in-vivo physiological quantification of murine subcutaneous tumor allografts

et al. 2018

View full text Add to dashboard Cite

show abstract

“…CXCR4 antibody significantly reduces monocyte recruitment. MM secretes CCL2, which induces the expression of monocyte chemotactic protein-1-induced protein 1(MCPIP1) in macrophages via the JAK2-STAT3 pathway, promoting macrophage homing, proliferation, and M2-like phenotypic polarization ( 33 , 34 ). Consequently, CCR2 monoclonal antibodies or inhibitors can disrupt macrophage recruitment in MM ( 146 , 147 ).…”

Section: Treatment Targeting MM Microenvironment Componentsmentioning

confidence: 99%

Advancements in microenvironment-based therapies: transforming the landscape of multiple myeloma treatment

Lu,

Wang,

Liu

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Multiple myeloma (MM) is the most prevalent malignant monoclonal disease of plasma cells. There is mounting evidence that interactions with the bone marrow (BM) niche are essential for the differentiation, proliferation, survival, migration, and treatment resistance of myeloma cells. For this reason, gaining a deeper comprehension of how BM microenvironment compartments interact with myeloma cells may inspire new therapeutic ideas that enhance patient outcomes. This review will concentrate on the most recent findings regarding the mechanisms of interaction between microenvironment and MM and highlight research on treatment targeting the BM niche.

show abstract

Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

Untitled

Cited by 10 publications

References 5 publications

Sampling depth of a diffuse reflectance spectroscopy probe for in-vivo physiological quantification of murine subcutaneous tumor allografts

Sampling depth of a diffuse reflectance spectroscopy probe for in-vivo physiological quantification of murine subcutaneous tumor allografts

Advancements in microenvironment-based therapies: transforming the landscape of multiple myeloma treatment

Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer

Contact Info

Product

Resources

About